While the UK's world-class universities provide a rich pipeline of scientific talent for biotechs, the country's clinical trial infrastructure is a significant hurdle. Immense pressure on the NHS creates delays in site opening and patient recruitment, creating a fundamental friction point in the biotech value chain.

While biotech is seeing renewed investor interest after being 'left for dead,' its culture differs from mainstream tech. Instead of chasing unicorn-or-bust 'power law' outcomes, the biotech community often prioritizes more frequent, smaller exits in the low billions, creating a pattern of 'base hits' and serial entrepreneurship.

The CEO of NervGen explicitly states his goal is to commercialize their spinal cord injury drug independently, not to position the company for an acquisition. This long-term, mission-driven focus on getting a drug to market shapes strategic decisions and contrasts with a common build-to-sell mentality in biotech.

Founder Fred Turner notes a key cultural difference: UK investors focus on credentials and mitigating worst-case scenarios, asking 'how do I not get fired?'. In contrast, Silicon Valley investors focus on the maximum possible outcome, asking 'how big could this be in ten years?', making them more open to young, unproven founders.

A key cultural difference in venture capital is that European VCs often request late-stage metrics like five-year financial projections from pre-seed companies. This contrasts sharply with the US/SF focus on market size, team, and vision at the earliest stages of a company's life.

The dominant biotech VC model incentivizes startups to act like real estate developers: build an asset to a certain stage (e.g., early clinical data) and then sell it to a large pharmaceutical company. This focus on short-term exits discourages the long-term, ambitious company-building required for revolutionary platforms.

The US biotech ecosystem thrives because failure is viewed as a valuable learning experience. In contrast, European culture often penalizes entrepreneurs from failed startups, creating a more risk-averse environment that stifles innovation and limits the pool of experienced operators who are willing to try again.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

Europe's strong science is often held back by a lack of serial entrepreneurs, difficulty in raising follow-on funding, and a localized competitive view. Curie.Bio’s model directly counters these issues by providing an experienced drug-making team, a clear funding path, and an embedded global market perspective.